department of health and human services …fdagov-afda-orgs/...during the pq testing the firm did...

4
SEE REVERSE OF THIS PAGE FORM FDA 483 (09/08) Marc S Ne ub auer , I nves tigato r 10/24/2 011 PAGE 1 OF 4 PAGES DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMlNlSTRATJON DISTRICT AOOilESS AND PHONE NUMBER 158-1 5 Liberty Ave. Jamaica, NY 11433 (718) 340-7000 Fax: (7 18) 662-5661 Industry Information: www.fda.gov /o c/industr y DATE(S) OF INSPECTlON 10/14 /20 11 - 10/24 /2011 * FEINUMBER 3005 72476 3 >lAME AND TITLE OF INCIVICUAI. TO 'Mioo.l REPORT ISSUED TO: James Della Valle, Vice President Distribution FIRM NAME CooperVision Inc. STREET ADDRESS 180 Th r u way Park Dr CITY, STATE, ZIP CODE, COUNTRY W Henri e tta, NY 1458 6 -9798 TYPE ESTABLISHMENT INSPECTED Packager/Labe1er This document lists observations made by the fDA reprcscntativc(s) during the inspection of your facility. They arc inspcctional observations, and do not represent a final Agency detennination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this infonnation to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements. DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures. Specifically, the I (b) (4) .1 packaging lines that are operated by th (b) (4) and (b) (4) machines are not adequately validated according to established procedures. Performance Qualification: I) The firm relies on the machines to perform quality checks to determine ifthe label information was printed correctly on the blisters. During the PQ testing the firm did not open up the cartons to see if the blisters inside had the correct label information or if the label information printed on the blisters matched the label information printed on the cartons. 2) The procedure did not define the number of runs or the number of units per run. In addition, the procedure did not define the statistical analysis methods that would be used or the number of data points that would be needed for the statistical analysis. In practice, these machines on average label (b) (4) __J cartons per month and each run (lot) is typically - (b) (4) units. During PQ, the firm tested. (b) (4) runs with r--- (b) (4) I units per run. 3) The firm did not document the type of errors they obtained (i.e. incorrect labeling information on carton, damaged package, etc.) even though these errors are defined in the procedure. Installation Qualification and Operational Qualification: I) The results for the testing performed during IQ were not adequately documented. For some sections the flffiljust stated pass or fail for the overall section and not for the individual tests that were performed within that section. 2) The firm stated they use the preventative maintenance schedule that is outlined in the owner's manual for these. (b) (4) \

Upload: phunghanh

Post on 01-Apr-2018

213 views

Category:

Documents


0 download

TRANSCRIPT

~--------------~EM~~~ow~~E~~~~~~w~~~-----------------------------------------------------,nMA,TE~I~~Dn-----,

SEE REVERSE OF THIS PAGE

FORM FDA 483 (09/08)

Marc S Ne ubauer , I nvestigator 10 / 2 4 / 2011

PAGE 1 OF 4 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMlNlSTRATJON

DISTRICT AOOilESS AND PHONE NUMBER

158-1 5 Liberty Ave. Jamaica, NY 11433 (718) 340-7000 Fax: (7 18) 662-5661 Industry Information: www.fda.gov/oc/industry

DATE(S) OF INSPECTlON

10/14 /20 11 - 10/24 /2011 * FEINUMBER

3005724763

>lAME AND TITLE OF INCIVICUAI. TO 'Mioo.l REPORT ISSUED

TO: James Della Valle, Vice President Distribution FIRM NAME

CooperVision Inc. STREET ADDRESS

180 Thr uway Park Dr CITY, STATE, ZIP CODE, COUNTRY

W Henrie tta, NY 1458 6-9798 TYPE ESTABLISHMENT INSPECTED

Packager/Labe1er

This document lists observations made by the fDA reprcscntativc(s) during the inspection of your facility. They arc inspcctional observations, and do not represent a final Agency detennination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this infonnation to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures.

Specifically, the I (b) (4).1 packaging lines that are operated by th (b) (4) and (b) (4)machines are not adequately validated according to established procedures.

Performance Qualification:

I) The firm relies on the machines to perform quality checks to determine ifthe label information was printed correctly on the blisters. During the PQ testing the firm did not open up the cartons to see if the blisters inside had the correct label information or if the label information printed on the blisters matched the label information printed on the cartons.

2) The procedure did not define the number of runs or the number of units per run. In addition, the procedure did not define the statistical analysis methods that would be used or the number of data points that would be needed for the statistical analysis. In practice, these machines on average label and~ (b) (4)__J cartons per month and each run (lot) is typically -(b) (4) units. During PQ, the firm tested.

(b) (4)runs with r---(b) (4) I units per run.

3) The firm did not document the type of errors they obtained (i.e. incorrect labeling information on carton, damaged package, etc.) even though these errors are defined in the procedure.

Installation Qualification and Operational Qualification:

I) The results for the testing performed during IQ were not adequately documented. For some sections the flffiljust stated pass or fail for the overall section and not for the individual tests that were performed within that section.

2) The firm stated they use the preventative maintenance schedule that is outlined in the owner's manual for these. (b) (4)\

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER DA TE(S) Of' INSPECTION

158-15 Liberty Ave. 10/14 / 2 0 11 - 10/2 4 /2011 * Jamaica, NY 11433 FEINUMI!ER

( 718) 340-7000 Fax: (7 18) 662-5661 30057247 63 Industry Info rmation: www.fda.go v /oc/industry NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED

TO: James Della Valle, Vice Pre sident Distribut i on FIRM NAME STREET ADDRESS

CooperVision Inc. 180 Thruway Park Dr CITY, STATE. ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED

W Henrietta, NY 14586-9798 Package r/Labeler

EMPLOYEE($) SIGNATURE DATE ISSUED

SEE REVERSE Marc S Ne~uer , In vestigator 1 0 / 2 4 /2011

OF THIS PAGE /V\ ·~ fl.

FORM FDA 483 (09/08) PREVIOUS EVITJON OBSOLETE INSPECTIONAL OBSERVATIONS PAGF 2 OF 4 PAGES

machines. The manual calls for i. (b) (4) .I cleaning of the sensors that are used to read the bar code off the silver stock (unlabeled blisters), the label information that is printed on the blisters and the information that is printed on the cartons. In practice, the firm cleans these sensors once every

(b) (4)

weeks. The frrm did not perform any testing during 0Q to determine the ability of the sensors to perform their function ifthey are not maintained according to the preventive maintenance requirements outlined in the manual.

OBSERVATION 2

Procedures for finished device acceptance have not been established.

Specifically, the firm has not established procedures for finished device acceptance for labeling operations for any of its products.

OBSERVATION 3

Procedures for device history records have not been established.

Specifically, the firm has not established a procedure for device history records.

OBSERVATION 4

Procedures for corrective and preventive action have not been adequately established.

Specifically, the finn did not implement its procedure, Corrective and Preventive Action, SOP Number QAP082, Revision Number II, for initiating a CAPA when required by its Risk Assessment Matrix. If the Risk Assessment number falls into the Red categories on the Risk Assessment Matrix, a CAPA must be raised. For its labeling operations if a complaint or non conforming report is categorized as a P5-mislabeled for the fo1lowing reasons then it falls into the Red category and a CAP A must be opened: incorrect human readable information on the primary packaging label, incomplete/illegible information on secondary packaging or no insert included in the secondary packaging. The following complaints and non conforming reports should have had a CAPA initiated.

I) Complaint CC136149- Category: P5-Mislabeled, Product: Proclear Toric, Description: box does not match blisters

2) Complaint CC144253- Category: P5-Mislabled, Product: MINI, Description: lens label states tinted and this product is not actually tinted.

3) Complaint CC161176- Category: P5-Mislabled, Product: Hydrasoft Toric, Description: last vial in box was incorrect. Outside ofpackage marked 8.3/14.2 10-25-l.75x50. Last vial in box is 8.9115.0 500-2.50xl70.

4) Complaint CC161446- Category: P5-Mislabeled, Product: Biomedics Toric, Description: carton is labeled -4.00-1.75x 120 and blisters are labeled -2.50-1.75X50.

\

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

DISTRICT ADDRESS AND PHONE NUMBER DA TE(S) OF INSPECTION

158-15 Liberty Ave. Jamaica, NY 11433

10/14/2011 - 10/24/2011* FEINUMBER

(718) 340-7000 Fax: (718) 662-5661 3005724763 Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDI\IIDUAL TO WHOM REPORT ISSUED

TO: James Della Valle, Vice President Distribution FIRM NAME STREET ADDRESS

CooperVision Inc. 180 Thruway Park Dr CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED

W Henrietta, NY 14586-9798 Packager/Labeler

SEE REVERSE OF THIS PAGE

FORM FDA 483 (09/08)

EMPLDYEE(S) SIGNATURE

~ S Neubauer,

/v1<:: Ill ' -r v

PREVIOUS EDITION OBSOLETE

DATE ISSUED

Investigator 10/24/2011

INSPf:CTIONAL OBSERVATIONS PAGE 1 OF 4 PAGES

5) Non Conforming Report NCR83768- Category: Secondary packaging process, Description: QA- 3 cartons that were opened by Auditor did not have inserts in them.

OBSERVATION 5

Complaints involving the possible failure of labeling to meet any of its specifications were not investigated where necessary.

Specifically, the firm did not do a root cause investigation for the following complaints that dealt with mislabeling:

1) Complaint CC 136149 - Category: P5-Mislabeled, Product: Proclear Toric, Description: box does not match blisters

2) Complaint CC144253- Category: P5-Mislabled, Product: MINI, Description: lens label states tinted and this product is not actually tinted.

3) Complaint CC 161176 - Category: P5-Mislabled, Product: Hydrasoft Toric, Description: last vial in box was incorrect. Outside ofpackage marked 8.3/14.2 10-25-1.75x50. Last vial in box is 8.9115.0 500-2.50x170.

4) Complaint CCI61446- Category: P5-Mislabeled, Product: Biomedics Toric, Description: carton is labeled -4.00-1.75xl20 and blisters are labeled -2.50-1.75X50.

Specifically, the firm did not perform a root cause investigation nor did they determine whether the issues extended to other lots for the following unconfirmed complaints.

1) Complaint CC143835- Product: Biomedics 55 UV, Description: Box is labeled -3.75 and two lenses inside the box are +3.25.

2) Complaint CC146840- Product: Proclear Toric, Description: Patient claims that 2 +475- 1.75 10 lenses were in a box that was labeled +5.75- 1.75 60.

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMTNISTRA TION

DISTRICT ADDRESS AND PHONE NUMBER DA TE(S) OF INSPECTION

158-15 Liberty Ave. Jamaica, NY 11433

10/14/2011 - 10/24/2011* FEI NUMBER

(718) 340-7000 Fax: (718) 662-5661 3005724763 Industry Information: www.fda.gov/oc/industry NAME AND TITLE OF INDIVIDUAL TO \I\IHOM REPORT ~ED

TO: James Della Valle, Vice President Distribution FIRM NAME STREET ADDRESS

CooperVision Inc. 180 Thruway Park Dr CITY, STATE. ZIP CODE, COUNTRY TYPE ESTABUSHMENT INSPECTED

W Henrietta, NY 14586-9798 Packager/Labeler

Observation Annotations

Observation I: Promised to correct within 24 weeks. Observation 2: Promised to correct within 24 weeks. Observation 3: Promised to correct within 24 weeks. Observation 4: Promised to correct within 24 weeks. Observation 5: Promised to correct within 24 weeks.

*DATES OF INSPECTION: I0/14/2011(Fri), 10/17/20li(Mon), 10/18/201l(Tue), I0/20/20ll(fhu), 10/24/2011(Mon)

EMPLOYEE($) SIGNATURE DATE ISSUED

Marc S Neubauer, Investigator SEE REVERSE 10/24/2011 OF THIS PAGE 15riL- ·/)11. L,,,,.......-

\' '.__. " <:::::"'

FORM FDA 483 (09108) PREVIOUS EDITION OBSOI,ETE

-­INSPF:CTIONAL OBSERVATIONS PAGF 4 Of 4 PAGFS